Welcome to our dedicated page for Arch Biopartners news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on Arch Biopartners stock.
Arch Biopartners Inc. develops therapeutics for acute kidney injury and chronic kidney disease. Company news centers on LSALT peptide for cardiac surgery-associated acute kidney injury, cilastatin for drug-toxin-related acute kidney injury, and a chronic kidney disease platform tied to interleukin-32.
Recurring updates include clinical trial agreements, ethics and operational approvals, hospital site activity, patient recruitment and dosing milestones, drug-product manufacturing for cilastatin, patent filings connected with the CKD platform, and board governance changes. The company’s disclosures also describe acute kidney injury mechanisms such as ischemia-reperfusion injury, nephrotoxic pharmaceuticals, and inflammation-related kidney damage.
Arch Biopartners Inc. has commenced its Phase II trial of LSALT peptide, aimed at preventing acute lung and kidney injuries in COVID-19 patients. The first patient was dosed at Broward Health Medical Center, with recruitment expanding soon to Louisiana and Turkey. This international, double-blind trial will assess LSALT's efficacy in mitigating severe organ inflammation connected to COVID-19 complications. Results will inform the design of a subsequent Phase III trial, which will involve a larger patient population.
Arch Biopartners Inc. (OTCQB: ACHFF) has received approval from Turkey's Ministry of Health to proceed with a Phase II trial for its LSALT peptide drug, targeting acute lung and kidney injuries related to COVID-19. Patient enrollment will commence in Istanbul and Ankara, amidst rising COVID-19 cases in Turkey. In the U.S., patient screening has begun at a hospital site in Florida, with plans to activate two more sites. The trial aims to assess the LSALT peptide's efficacy in preventing organ inflammation in COVID-19 patients, impacting future Phase III study designs.